INTERNATIONAL NEUROLOGICAL JOURNAL | 2021

Pramipexole extended release: new options for continuous dopaminergic stimulation in Parkinson’s disease

 

Abstract


The most important approach to dopaminergic stimulation in Parkinson’s disease is the use of dopamine agonists. Compared with levodopa agents, dopamine agonists are characterized by a lower risk of drug-induced dyskinesia and motor fluctuations, no need for brain metabolism and the neuroprotective potential established in the experiment. One of the most effective drugs in this group is pramipexole — a synthetic benzothiazole derivative (tetrahydrobenzothiazole). Pramipexole is a potent D2-receptor agonist with maximal affinity for the D3-receptor subtype. Stimulation of D2-receptors of the basal ganglia provides the effect of the drug on motor manifestations of the disease, while stimulation of D3-receptors of the limbic system reduces non-motor manifestations, including a positive effect on neuropsychological status and reduced severity of depressive syndrome in patients with Parkinson’s disease. The effectiveness of pramipexole has been proven by numerous studies both in the early stages of Parkinson’s disease — as monotherapy and in the advanced stages — in combination with levodopa agents. With the development of the disease, the scheme of its treatment became more complex due to an increase in the number of drugs taken and the frequency of their administration. This inevitably creates a problem of insufficient adherence of patients to treatment. In this regard, a new dosage form of pramipexole has been developed — long-acting pramipexole, which ensures its extended release and allows a single dose during the day. This not only makes the treatment of the patient more convenient, but also improves the adherence of patients to treatment, increases the long-term effectiveness of therapy. In addition, with the slow release of pramipexole during the day, its concentration in the blood is more stable, which can provide better tolerance and effective control of symptoms of the disease throughout the day (both during the day and at night).

Volume 17
Pages 29-33
DOI 10.22141/2224-0713.17.3.2021.231574
Language English
Journal INTERNATIONAL NEUROLOGICAL JOURNAL

Full Text